With its rep on the line, Cel­gene's new­ly-filed safe­ty study spurs fresh wor­ries over fate of ozan­i­mod

Af­ter blun­der­ing its way in­to an ug­ly set­back at the FDA with its high­ly an­tic­i­pat­ed mul­ti­ple scle­ro­sis drug ozan­i­mod, Cel­gene is trig­ger­ing fresh ques­tions about the fu­ture of this fre­quent­ly tout­ed block­buster-to-be with a slate of new­ly filed clin­i­cal tri­als aimed at fur­ther ex­plor­ing pos­si­ble safe­ty is­sues. And that has at least one promi­nent an­a­lyst won­der­ing if he will need to even­tu­al­ly re­cal­cu­late the tim­ing — and chances of suc­cess — of the mar­ket­ing pitch.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER